Related Experiment Video
Updated: May 15, 2026
02:22
Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
Published on: April 12, 2024
Treatment modalities for intractable epilepsy in hypothalamic hamartoma
Joong-Uhn Choi1, Dong-Seok Kim
1Department of Neurosurgery, CHA University, Sungnam, Gyeonggi-do, Korea. juchoi@cha.ac.kr
Advances and Technical Standards in Neurosurgery
|December 20, 2012
Summary
Hypothalamic hamartoma (HH) can be effectively treated using various neurosurgical methods for epilepsy and cognitive issues. Surgical options like resection and disconnection offer favorable outcomes for patients with intractable gelastic seizures.
Area of Science:
- Neurology
- Neurosurgery
Background:
- Hypothalamic hamartoma (HH) is a rare brain malformation.
- It is frequently linked to refractory epilepsy, cognitive deficits, and behavioral problems.
Purpose of the Study:
- To review current neurosurgical treatment options for hypothalamic hamartoma.
- To discuss the selection of appropriate treatment modalities for patients with intractable gelastic seizures.
Main Methods:
- Overview of surgical interventions including open craniotomy, endoscopic surgery, Gamma Knife radiosurgery (GKS), and stereotactic radiofrequency thermocoagulation.
- Discussion of surgical techniques such as resection and disconnection.
- Consideration of pretreatment evaluation and patient selection criteria.
Main Results:
- Various neurosurgical approaches demonstrate effectiveness in treating HH.
- Both resection and disconnection techniques have shown favorable outcomes.
- Treatment modality selection is influenced by HH characteristics and surgeon preference.
Conclusions:
- Neurosurgical interventions offer effective treatment for hypothalamic hamartoma.
- Careful patient selection and appropriate technique choice are crucial for successful outcomes.
- Further research into optimizing treatment strategies for HH is warranted.
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...